Skip to main content

Edwards Lifesciences Corp Value Stock - Dividend - Research Selection

Edwards lifesciences

ISIN: US28176E1082 , WKN: 936853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Edwards Lifesciences Soars on TTVR Approval, But Challenges Remain

2024-10-08
Medical device company Edward Lifesciences sees stock jump on milestone, but upcoming divestiture raises concerns

CMS begins national coverage review for tricuspid repair

2024-10-08
The agency will consider national reimbursement for new tricuspid transcatheter repair devices, including Abbott’s Triclip, in Medicare patients with a leaky tricuspid heart valve.

Edwards Lifesciences Corp (EW) Stock Price Up 6.14% on Oct 8

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Edwards Lifesciences price target lowered to $66 from $77 at Canaccord

2024-10-08
Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences to $66 from $77 and keeps a Buy rating on the shares. The firm updatied its model post the sale of critical care business and commentary from September investor conferences. Canaccord believes 2025 is expected to be a transition year for EW post the sale of the Critical Care business to Becton Dickinson in early September 2024 for $4.2B. Published first on TheFly – the ultimate source for real-time, market

Edwards Lifesciences call volume above normal and directionally bullish

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Edwards Lifesciences price target lowered by $10 at RBC Capital, here's why

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Piper Sandler Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Edwards Lifesciences (EW) Stock Jumps 5% Amid Strong Earnings Report

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

TFX vs. EW: Which Stock Is the Better Value Option?

2024-10-07
TFX vs. EW: Which Stock Is the Better Value Option?

Maintaining Hold on Edwards Lifesciences Amid Transition and Earnings Adjustment

2024-10-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.